


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-2.13%
+0.69%
-2.08%
+0.82%
-8.52%
ALKS
Alkermes plc
$29.10
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Trading below its fair value

Outperform the market
ALKS Price Performance
$32.89 (-11.52%)
$27.71 (+5.02%)
$29.2 (-0.34%)
$30.07 (-3.23%)
ALKS has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

ALKS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Revenue increase YoY

Earnings increase YoY

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
ALKS Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
ALKS Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is ALKS current stock price?
What are ALKS stock strengths?
What is ALKS Risk Level?
What is ALKS market cap and volume?
What is ALKS current Stock IQ?
Should I buy ALKS stock right now?
Is ALKS a Strong Buy right now?
What does a 'Strong Buy' rating mean for ALKS?
What does a 'Strong Sell' rating mean for ALKS?
What factors influence ALKS's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.13%
+0.69%
-2.08%
+0.82%
-8.52%
ALKS
Alkermes plc
Current Price
$29.10
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Trading below its fair value

Outperform the market

ALKS Price Performance
$32.89 (-11.52%)
$27.71 (+5.02%)
$29.2 (-0.34%)
$30.07 (-3.23%)
ALKS Analysts Opinion
ALKS Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Revenue increase YoY

Earnings increase YoY

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
ALKS Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
ALKS Street Sentiment is extremely bullish and have positive views on the near-term outlook
ALKS has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
ALKS Stock IQ
ALKS Latest Analysis
ALKS Raises Its Offer to Buy Avadel In Response to Lundbecks Proposal. Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deals momentum.
Thu Nov 20, 2025
Alkermes Ups Its Avadel Bid To $2.37 Billion In A Buyout Battle With Lundbeck. Alkermes upped its bid on Avadel to $2.37 billion on Wednesday coming in with the superior proposal vs. Lundbecks unexpected pitch.The post Alkermes Ups Its Avadel Bid To $2.37 Billion In A Buyout Battle With Lundbeck appeared first on Investor'.s Business Daily.
Wed Nov 19, 2025
Alkermes raises Avadel buyout offer after Lundbecks unsolicited bid.
Wed Nov 19, 2025
TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment. Alkermes Plc (NASDAQ:ALKS) is one of the best breakout stocks to invest in. On November 12 Alkermes Plc (NASDAQ:ALKS) delivered positive topline clinical trial data for its narcolepsy treatment Alixorexton. Consequently analysts at TD Cowen reiterated a Buy rating on the stock with a $40 price target. Alixorexton formerly ALKS 2680 is the companys candidate [….]
Wed Nov 19, 2025
Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal. AVDLs board calls Lundbecks higher $23-per-share bid superior to its Alkermes deal triggering a critical five-day response window.
Tue Nov 18, 2025
Truist Securities Maintains Alkermes (ALKS) Buy Recommendation. Fintel reports that on November 17 2025 Truist Securities maintained coverage of Alkermes (NasdaqGS:ALKS) with a Buy recommendation. Analyst Price Forecast Suggests 51.50% Upside
Tue Nov 18, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ALKS Stock trends
ALKS Stock performance
ALKS Stock analysis
ALKS investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.